Choose Your Country or Region

Oxybutynin hydrochloride

Name: Oxybutynin hydrochloride
Brand: Selleck Chemicals
SKU: S3117
Rating: 5 (1 reviews)

Synonyms: MJ4309-1

Catalog No.S3117 Purity:98.39%

Oxybutynin(MJ4309-1) is an anticholinergic medication used to relieve urinary and bladder difficulties.

Oxybutynin hydrochloride Chemical Structure

CAS No. 1508-65-2

Purity & Quality Control

Batch: S311701 DMSO]79 mg/mL]false]Ethanol]79 mg/mL]false]Water]4 mg/mL]false Purity: 98.39%

98.39

Oxybutynin hydrochloride Related Products

Related Targets	mAChR nAChR AChE	Click to Expand
Related Products	PNU-120596 Benzethonium Chloride Arecoline HBr Otilonium Bromide Lycorine Hyoscyamine (-)-Huperzine A (HupA) Nitenpyram Cytisine Chelidonine	Click to Expand
Related Compound Libraries	FDA-approved Drug Library Natural Product Library Neuronal Signaling Compound Library CNS-Penetrant Compound Library Anti-alzheimer Disease Compound Library	Click to Expand

Signaling Pathway

AChR Signaling Pathway

Biological Activity

Description

Oxybutynin(MJ4309-1) is an anticholinergic medication used to relieve urinary and bladder difficulties.

Targets

mAChR ^[1]

In vitro
In vitro	Oxybutynin relieves urinary and bladder difficulties, including frequent urination and inability to control urination (urge incontinence), by decreasing muscle spasms of the bladder. Oxybutynin competitively antagonizes the M1, M2, and M3 subtypes of the muscarinic acetylcholine receptor. ^[1] Oxybutynin also has direct spasmolytic effects on bladder smooth muscle as a calcium antagonist and local anesthetic, but at concentrations far above those used clinically. ^[2]

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2024-05-22)
NCT05637671	Recruiting	Vasomotor Symptoms	Cairo University	February 10 2022	Phase 3
NCT04526353	Unknown status	Male Urogenital Diseases	University Hospital Bordeaux	September 10 2020	Phase 2
NCT02522936	Withdrawn	Overactive Bladder\|Xerostomia\|Compliance	University of Southern California	August 1 2018	Phase 4
NCT02099695	Withdrawn	Hyperhidrosis	Cristália Produtos Químicos Farmacêuticos Ltda.\|Hospital Israelita Albert Einstein\|University of Sao Paulo	December 2015	Phase 3

References

Chemical Information & Solubility

Molecular Weight	393.95	Formula	C₂₂H₃₁NO₃.HCl
CAS No.	1508-65-2	SDF	Download Oxybutynin hydrochloride SDF
Smiles	CCN(CC)CC#CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O.Cl
Storage (From the date of receipt)	3 years-20°Cpowder	Storage of Stock Solutions Aliquot the stock solutions to avoid repeated freeze-thaw cycles	1 year-80°Cin solvent
Storage (From the date of receipt)	3 years-20°Cpowder		1 month-20°Cin solvent

In vitro
Batch:

DMSO : 79 mg/mL ( (200.53 mM) Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Ethanol : 79 mg/mL

Water : 4 mg/mL

Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.

In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):